Security
Whitehawk Therapeutics, Inc. Common Stock · WHWK
WHWKNASDAQCommon stockCurrentCIK 1422142Updated Oct 6, 2026
Name history
Aadi Bioscience, Inc. · through Mar 18, 2025Aerpio Pharmaceuticals, Inc. · through Aug 23, 2021ZETA ACQUISITION CORP II · through Mar 13, 2017
WHWK price & chart
Loading TradingView…
NASDAQ:WHWK on TradingView ↗About the company
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk’s portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.
In the news
Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights News provided by Whitehawk Therapeutics, Inc. Aug 07, 2025, 08:00 ET Share this article Share to X Share this article Share to X MORRISTOWN, N.J. , Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Na ↗
Seeking Alpha
Whitehawk Therapeutics, Inc. (WHWK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript ↗
Whitehawk Therapeutics: 'Hold' On Name Change And Next Generation PTK7 ADC Targeting ↗
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
SCHEDULE 13G/A - filed by ABG Management Ltd. regarding Whitehawk Therapeutics, Inc.
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Show 5 more recent filings
4 filing
Submission of Matters to a Vote of Security Holders
Items 5.07
EFFECT filing
S-3 filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 167,017,000Source | 85,698,000Source | 193,994,000Source | 180,822,000Source | 101,620,000Source | 127,231,000Source | 234,002,000Source | 111,073,000Source | 150,830,000Source | 70,319,000Source | 132,423,000Source | 184,237,000Source |
| Property, Plant and Equipment, NetUSD | 4,000Source | 5,982,000Source | 1,000Source | 9,000Source | 6,004,000Source | 2,000Source | 25,000Source | 5,686,000Source | 3,000Source | 6,846,000Source | 4,802,000Source | 508,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 37,931,000Source | 30,537,000Source | 85,234,000Source | 144,936,000Source | 41,139,000Source | 34,790,000Source | 227,569,000Source | 53,780,000Source | 37,568,000Source | 28,670,000Source | 62,888,000Source | 39,019,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 6,540,000Source | — | 0Source | 5,920,000Source | — | 0Source | 4,933,000Source | 0Source | 5,903,000Source | 5,488,000Source | 1,862,000Source |
| Inventory, NetUSD | 0Source | 5,468,000Source | — | 0Source | 6,098,000Source | — | 0Source | 5,936,000Source | 0Source | 5,311,000Source | 6,427,000Source | 1,861,000Source |
| Assets, CurrentUSD | 165,036,000Source | 77,315,000Source | 192,414,000Source | 178,671,000Source | 93,005,000Source | 125,548,000Source | 232,614,000Source | 102,573,000Source | 149,013,000Source | 61,287,000Source | 124,586,000Source | 180,029,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,439,000Source | 2,688,000Source | 2,432,000Source | 1,471,000Source | 2,419,000Source | 2,505,000Source | 1,552,000Source | 3,433,000Source | 3,316,000Source | 2,836,000Source | 3,826,000Source | 3,746,000Source |
| Operating Lease, Right-of-Use AssetUSD | 0Source | 886,000Source | — | 0Source | 982,000Source | — | 0Source | 1,077,000Source | 0Source | 787,000Source | 1,169,000Source | 1,522,000Source |
| Other Assets, NoncurrentUSD | 1,977,000Source | 1,515,000Source | 1,579,000Source | 2,142,000Source | 1,629,000Source | 1,681,000Source | 1,363,000Source | 1,737,000Source | 1,814,000Source | 1,399,000Source | 1,866,000Source | 2,178,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 9,849,000Source | 16,830,000Source | 11,069,000Source | 8,756,000Source | 22,829,000Source | 11,056,000Source | 12,274,000Source | 20,613,000Source | 14,519,000Source | 17,841,000Source | 27,228,000Source | 25,859,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 4,000Source | 2,000Source | 5,000Source | 4,000Source | 2,000Source | 4,000Source | 4,000Source | 2,000Source | 4,000Source | 2,000Source | 2,000Source | 2,000Source |
| Retained Earnings (Accumulated Deficit)USD | -329,999,000Source | -314,381,000Source | -392,084,000Source | -312,253,000Source | -301,835,000Source | -375,444,000Source | -259,638,000Source | -287,252,000Source | -353,250,000Source | -332,654,000Source | -268,963,000Source | -203,198,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 139,000Source | 39,000Source | -63,000Source | 9,000Source | -27,000Source | -15,000Source | 1,000Source | -8,000Source | 120,000Source | 16,000Source | 27,000Source | -115,000Source |
| Stockholders' Equity Attributable to ParentUSD | 157,168,000Source | 68,868,000Source | 182,925,000Source | 172,066,000Source | 78,791,000Source | 116,175,000Source | 221,728,000Source | 90,460,000Source | 136,311,000Source | 52,478,000Source | 105,195,000Source | 158,378,000Source |
| Additional Paid in Capital, Common StockUSD | 487,024,000Source | 383,208,000Source | 575,067,000Source | 484,306,000Source | 380,651,000Source | 491,630,000Source | 481,361,000Source | 377,718,000Source | 489,437,000Source | 385,114,000Source | 374,129,000Source | 361,689,000Source |
| Liabilities and EquityUSD | 167,017,000Source | 85,698,000Source | 193,994,000Source | 180,822,000Source | 101,620,000Source | 127,231,000Source | 234,002,000Source | 111,073,000Source | 150,830,000Source | 70,319,000Source | 132,423,000Source | 184,237,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 9,849,000Source | 15,813,000Source | 11,069,000Source | 8,756,000Source | 22,147,000Source | 11,056,000Source | 12,274,000Source | 19,875,000Source | 14,519,000Source | 17,074,000Source | 26,395,000Source | 18,835,000Source |
| Operating Lease, Liability, CurrentUSD | 0Source | 322,000Source | — | 0Source | 374,000Source | — | 0Source | 425,000Source | 0Source | 268,000Source | 434,000Source | 394,000Source |
| Accounts Payable, CurrentUSD | 1,633,000Source | 1,374,000Source | 1,105,000Source | 3,339,000Source | 2,265,000Source | 1,745,000Source | 3,657,000Source | 3,095,000Source | 917,000Source | 2,159,000Source | 5,898,000Source | 3,519,000Source |
| Operating Lease, Liability, NoncurrentUSD | 0Source | 624,000Source | — | 0Source | 682,000Source | — | 0Source | 738,000Source | 0Source | 565,000Source | 833,000Source | 1,267,000Source |
| Other Liabilities, NoncurrentUSD | 0Source | 393,000Source | — | 0Source | — | — | 0Source | — | 0Source | 202,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 8,216,000Source | 14,117,000Source | 9,964,000Source | 5,417,000Source | 13,751,000Source | 9,311,000Source | 8,617,000Source | 10,598,000Source | 13,602,000Source | 14,647,000Source | 14,306,000Source | 14,922,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | 162,600,000Source | 62,600,000Source | 190,000,000Source | 177,200,000Source | 78,600,000Source | 123,000,000Source | 231,100,000Source | 88,300,000Source | 145,700,000Source | 47,200,000Source | 108,800,000Source | 172,600,000Source |
| Short-term InvestmentsUSD | 124,666,000Source | 32,082,000Source | 104,748,000Source | 32,264,000Source | 37,429,000Source | 88,253,000Source | 3,493,000Source | 34,491,000Source | 108,129,000Source | 18,567,000Source | 45,957,000Source | 133,541,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | — | — | 79,000Source | 193,000Source | 169,000Source | 159,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | 2,718,000Source | 2,557,000Source | 1,520,000Source | 3,087,000Source | 2,193,000Source | 1,680,000Source | 9,873,000Source | 10,839,000Source | 11,954,000Source | 9,643,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | 0Source | 1,000,000Source | 1,000,000Source | 415,000Source | 3,626,000Source | 1,862,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 0Source | -170,000Source | -170,000Source | -1,116,000Source | 3,265,000Source | 1,861,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -22,208,000Source | -11,864,000Source | -97,433,000Source | -59,550,000Source | -59,663,000Source | -49,640,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 19,430,000Source | 115,498,000Source | 11,891,000Source | 25,202,000Source | 83,206,000Source | -132,886,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 551,000Source | 552,000Source | 1,654,000Source | 3,972,000Source | 444,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 0Source | 95,201,000Source | 94,376,000Source | 130,000Source | 326,000Source | 72,620,000Source |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -2,778,000Source | 198,835,000Source | 8,834,000Source | -34,218,000Source | 23,869,000Source | -109,906,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 0Source | 211,000Source | 230,000Source | 230,000Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | — | -3,136,000Source | -1,215,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 87,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | 162,600,000Source | 62,600,000Source | 190,000,000Source | 177,200,000Source | 123,000,000Source | 231,100,000Source | 145,700,000Source | 47,200,000Source | 108,800,000Source | 172,600,000Source |
| DepreciationUSD | — | — | 5,600Source | 46,700Source | 1,000Source | 15,300Source | 1,000Source | 57,000Source | 100,000Source | 200,000Source | 200,000Source | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -1,000Source | -6,000Source | -3,000Source | — | 0Source | 5,000Source | -4,000Source | -1,000Source | — |
| Gain (Loss) on Disposition of BusinessUSD | — | — | -177,000Source | 0Source | 0Source | 0Source | 0Source | 87,443,000Source | 87,266,000Source | — | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 3,724,000Source |
| Impairment of Intangible Assets, Finite-livedUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 3,724,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 0Source | 38,000Source | — | 0Source | — | 0Source | 0Source | 154,000Source | — | — |
| Investment Income, InterestUSD | — | — | 1,850,000Source | 906,000Source | 1,475,000Source | 1,979,000Source | 1,328,000Source | 791,000Source | 6,231,000Source | 3,925,000Source | 6,400,000Source | 2,398,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,746,000Source | -12,546,000Source | -16,640,000Source | -52,615,000Source | -22,194,000Source | 73,016,000Source | -20,596,000Source | -63,691,000Source | -65,765,000Source | -60,513,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -60,513,000Source |
| Operating Lease, ExpenseUSD | — | — | 34,000Source | 115,000Source | 35,000Source | 34,000Source | 11,000Source | 74,000Source | 74,000Source | 460,000Source | 461,000Source | 382,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,800,000Source | 867,000Source | 1,469,000Source | 2,134,000Source | 1,328,000Source | 88,234,000Source | 93,804,000Source | 3,767,000Source | 6,168,000Source | 2,168,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | 0Source | 76,000Source | 16,000Source | 160,000Source | 337,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 0Source | 21,000Source | 26,000Source | 0Source | 78,000Source | 401,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 0Source | 7,212,000Source | 0Source | 0Source | 0Source | 7,145,000Source | 7,145,000Source | 25,983,000Source | 24,354,000Source | 15,216,000Source |
| Cost of RevenueUSD | — | — | 0Source | 804,000Source | 0Source | 0Source | 0Source | 760,000Source | 760,000Source | 3,024,000Source | 2,809,000Source | 1,335,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 5,201,000Source | 7,186,000Source | 5,216,000Source | 5,940,000Source | 6,290,000Source | 12,815,000Source | 29,822,000Source | 36,749,000Source | 44,549,000Source | 40,176,000Source |
| Operating Income (Loss)USD | — | — | -19,546,000Source | -13,413,000Source | -18,109,000Source | -54,749,000Source | -23,522,000Source | -15,218,000Source | -114,400,000Source | -67,458,000Source | -71,933,000Source | -62,681,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 1,800,000Source | 867,000Source | 1,469,000Source | 2,134,000Source | 1,328,000Source | 88,234,000Source | 93,804,000Source | 3,767,000Source | 6,168,000Source | 2,168,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | -16,640,000Source | -52,615,000Source | -22,194,000Source | 73,016,000Source | -20,596,000Source | -63,691,000Source | -65,765,000Source | -60,513,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -17,746,000Source | -12,546,000Source | -16,640,000Source | -52,615,000Source | -22,194,000Source | 73,016,000Source | -20,596,000Source | -63,691,000Source | -65,765,000Source | -60,513,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.26Source | -0.46Source | -0.2Source | -0.76Source | -0.32Source | 1.84Source | -0.33Source | -2.36Source | -2.44Source | -2.69Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.26Source | -0.46Source | -0.2Source | -0.76Source | -0.32Source | 1.83Source | -0.33Source | -2.36Source | -2.44Source | -2.69Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 69,204,899Source | 27,041,327Source | 82,886,196Source | 69,083,127Source | 69,236,945Source | 39,640,826Source | 61,886,765Source | 27,029,942Source | 26,917,967Source | 22,511,237Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 69,204,899Source | 27,041,327Source | 82,886,196Source | 69,083,127Source | 69,236,945Source | 39,932,539Source | 61,886,765Source | 27,029,942Source | 26,917,967Source | 22,511,237Source |
| Interest Expense (non-operating)USD | — | — | 0Source | 38,000Source | — | 0Source | — | 0Source | 0Source | 154,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 87,000Source |
| Costs and ExpensesUSD | — | — | 19,546,000Source | 20,625,000Source | 18,109,000Source | 54,749,000Source | 23,522,000Source | 22,363,000Source | 121,545,000Source | 93,441,000Source | 96,287,000Source | 77,897,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | 0Source | -1,000Source | -6,000Source | -3,000Source | — | 0Source | 5,000Source | -4,000Source | -1,000Source | — |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 231,000Source | 230,000Source |
| Investment Income, InterestUSD | — | — | 1,850,000Source | 906,000Source | 1,475,000Source | 1,979,000Source | 1,328,000Source | 791,000Source | 6,231,000Source | 3,925,000Source | 6,400,000Source | 2,398,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | — | — | — | — | — | — | — | -60,513,000Source |
| Operating Lease, ExpenseUSD | — | — | 34,000Source | 115,000Source | 35,000Source | 34,000Source | 11,000Source | 74,000Source | 74,000Source | 460,000Source | 461,000Source | 382,000Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Research and Development ExpenseUSD | — | — | 14,345,000Source | 9,997,000Source | 12,893,000Source | 48,809,000Source | 17,232,000Source | 8,788,000Source | 90,963,000Source | 51,030,000Source | 48,929,000Source | 32,662,000Source |
Offerings
Registration 333-296353
Filing attachments
d160342dex991.htm · 8-K · 2026-09-10
EX-99.1 2 d160342dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors Former Incyte Executive Brings Extensive Oncology, Corporate Strategy, Business Development and Medical Affairs Experience MORRISTOWN, N.J., September 10, 2026 /PRNewswire/ - Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently dev…
Read attachment ↗whwk-ex99_1.htm · 8-K · 2026-08-06
EX-99.1 2 whwk-ex99_1.htm EX-99.1 EX-99.1 PRESS RELEASE Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026 Cash, cash equivalents and short-term investments balance of $190.0 million as of June 30, 2026, anticipated to fund operations into 2H 2028 MORRISTOWN, NJ, August 6, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Na…
Read attachment ↗d32951dex991.htm · 8-K · 2026-05-21
EX-99.1 2 d32951dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Whitehawk Therapeutics Expands ADC Pipeline with New Option Agreement for Use of CPT113 Linker-Payload Agreement with Hangzhou DAC Provides Option for Up to Five New, Internally Developed ADC Programs, Including Dual-Payload Variations Hangzhou DAC’s DXC006 Data at ASCO Reinforce Conviction for CPT113, a Core Technology of Whitehawk’s ADC Platform Phase 1 Dose-Escalation Trials of HWK-007 and HWK-016 are Currently Enrolling; HWK-00…
Read attachment ↗d854431dex41.htm · 8-K · 2026-05-13
EX-4.1 2 d854431dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THESE SECURITIES REPRESENTED HEREBY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE BUT HAVE BEEN OR WILL BE ISSUED IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (i) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT …
Read attachment ↗d854431dex991.htm · 8-K · 2026-05-13
EX-99.1 5 d854431dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 PRESS RELEASE Whitehawk Therapeutics Announces $87.5M Private Placement Equity Financing MORRISTOWN, NJ, May 13, 2026 /PRNewswire/ - Whitehawk Therapeutics, Inc. (the “Company” or “Whitehawk”) (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced that it has entered …
Read attachment ↗whwk-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 whwk-ex99_1.htm EX-99.1 EX-99.1 PRESS RELEASE Whitehawk Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights Phase 1 trials for HWK-007 and HWK-016 are ongoing; an IND submission for HWK-206 is on track for mid-2026 Cash, cash equivalents and short-term investments balance of $123.0 million as of March 31, 2026, anticipated to fund operations into 2028 MORRISTOWN, NJ, May 7, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical…
Read attachment ↗